Voya Investment Management LLC Has $11.58 Million Holdings in Vaxcyte, Inc. $PCVX

Voya Investment Management LLC grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 306,729 shares of the company’s stock after purchasing an additional 5,169 shares during the period. Voya Investment Management LLC owned about 0.24% of Vaxcyte worth $11,582,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaQuest LLC bought a new stake in shares of Vaxcyte during the 1st quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Vaxcyte during the first quarter valued at $35,000. Parallel Advisors LLC raised its stake in shares of Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after acquiring an additional 1,071 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after acquiring an additional 1,306 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its stake in shares of Vaxcyte by 81.6% during the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after acquiring an additional 867 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective for the company. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $106.25.

Vaxcyte Price Performance

PCVX opened at $31.23 on Wednesday. The company’s 50-day moving average is $33.10 and its 200 day moving average is $38.42. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The firm has a market capitalization of $4.05 billion, a P/E ratio of -7.60 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the company earned ($1.10) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.